New hope for elderly leukemia patients: study tests gentler chemo combo
NCT ID NCT07132684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a newer, targeted drug combination (venetoclax plus azacitidine) works better than standard intensive chemotherapy for adults aged 55 to 75 with acute myeloid leukemia (AML). About 240 participants will be randomly assigned to one of the two treatments. The main goal is to see which approach helps people live longer, with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••